BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 19900619)

  • 1. Deciphering Rett syndrome with mouse genetics, epigenomics, and human neurons.
    Tao J; Wu H; Sun YE
    Int Rev Neurobiol; 2009; 89():147-60. PubMed ID: 19900619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neural development of methyl-CpG-binding protein 2 null embryonic stem cells: a system for studying Rett syndrome.
    Okabe Y; Kusaga A; Takahashi T; Mitsumasu C; Murai Y; Tanaka E; Higashi H; Matsuishi T; Kosai K
    Brain Res; 2010 Nov; 1360():17-27. PubMed ID: 20816763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-specific expression of wild-type MeCP2 in mouse models of Rett syndrome yields insight about pathogenesis.
    Alvarez-Saavedra M; Sáez MA; Kang D; Zoghbi HY; Young JI
    Hum Mol Genet; 2007 Oct; 16(19):2315-25. PubMed ID: 17635839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of disease: neurogenetics of MeCP2 deficiency.
    Francke U
    Nat Clin Pract Neurol; 2006 Apr; 2(4):212-21. PubMed ID: 16932552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The story of Rett syndrome: from clinic to neurobiology.
    Chahrour M; Zoghbi HY
    Neuron; 2007 Nov; 56(3):422-37. PubMed ID: 17988628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MeCP2 dysfunction in Rett syndrome and related disorders.
    Moretti P; Zoghbi HY
    Curr Opin Genet Dev; 2006 Jun; 16(3):276-81. PubMed ID: 16647848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postnatal loss of methyl-CpG binding protein 2 in the forebrain is sufficient to mediate behavioral aspects of Rett syndrome in mice.
    Gemelli T; Berton O; Nelson ED; Perrotti LI; Jaenisch R; Monteggia LM
    Biol Psychiatry; 2006 Mar; 59(5):468-76. PubMed ID: 16199017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains.
    Itoh M; Ide S; Takashima S; Kudo S; Nomura Y; Segawa M; Kubota T; Mori H; Tanaka S; Horie H; Tanabe Y; Goto Y
    J Neuropathol Exp Neurol; 2007 Feb; 66(2):117-23. PubMed ID: 17278996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MeCP2 expression and function during brain development: implications for Rett syndrome's pathogenesis and clinical evolution.
    Kaufmann WE; Johnston MV; Blue ME
    Brain Dev; 2005 Nov; 27 Suppl 1():S77-S87. PubMed ID: 16182491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rett syndrome: from the gene to the disease.
    Matijevic T; Knezevic J; Slavica M; Pavelic J
    Eur Neurol; 2009; 61(1):3-10. PubMed ID: 18948693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MeCP2 in neurons: closing in on the causes of Rett syndrome.
    Caballero IM; Hendrich B
    Hum Mol Genet; 2005 Apr; 14 Spec No 1():R19-26. PubMed ID: 15809268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MeCP2: structure and function.
    Adkins NL; Georgel PT
    Biochem Cell Biol; 2011 Feb; 89(1):1-11. PubMed ID: 21326358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A methyl-CpG-binding protein 2-enhanced green fluorescent protein reporter mouse model provides a new tool for studying the neuronal basis of Rett syndrome.
    Schmid RS; Tsujimoto N; Qu Q; Lei H; Li E; Chen T; Blaustein CS
    Neuroreport; 2008 Mar; 19(4):393-8. PubMed ID: 18287934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral and anatomical abnormalities in Mecp2 mutant mice: a model for Rett syndrome.
    Stearns NA; Schaevitz LR; Bowling H; Nag N; Berger UV; Berger-Sweeney J
    Neuroscience; 2007 May; 146(3):907-21. PubMed ID: 17383101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MeCP2 post-translational regulation through PEST domains: two novel hypotheses: potential relevance and implications for Rett syndrome.
    Thambirajah AA; Eubanks JH; Ausió J
    Bioessays; 2009 May; 31(5):561-9. PubMed ID: 19319913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MeCP2 mutation causes distinguishable phases of acute and chronic defects in synaptogenesis and maintenance, respectively.
    Palmer A; Qayumi J; Ronnett G
    Mol Cell Neurosci; 2008 Apr; 37(4):794-807. PubMed ID: 18295506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MeCP2 and other methyl-CpG binding proteins.
    Jørgensen HF; Bird A
    Ment Retard Dev Disabil Res Rev; 2002; 8(2):87-93. PubMed ID: 12112733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
    Gadalla KK; Bailey ME; Cobb SR
    Biochem J; 2011 Oct; 439(1):1-14. PubMed ID: 21916843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum and distribution of MECP2 mutations in 424 Rett syndrome patients: a molecular update.
    Philippe C; Villard L; De Roux N; Raynaud M; Bonnefond JP; Pasquier L; Lesca G; Mancini J; Jonveaux P; Moncla A; Chelly J; Bienvenu T
    Eur J Med Genet; 2006; 49(1):9-18. PubMed ID: 16473305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of cis-regulatory elements for MECP2 expression.
    Liu J; Francke U
    Hum Mol Genet; 2006 Jun; 15(11):1769-82. PubMed ID: 16613900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.